Search About company Counselor Company Presentations AGM Reports contact Polgenom Investor relations > Information about the company Informations about company Genomed SA made its debut on NewConnect on May 30, 2011. Information document_actions_seriaA2_27kwietnia_2017 Resolution of the Management Board of the Warsaw Stock Exchange Dokument informacyjny_cje_seriaB_17maja_2011 Resolution of the Management Board of the Warsaw Stock Exchange. The company provides services in the field of DNA sequencing, analysis and synthesis for over 200 research centers, biotechnology companies and medical institutions. The company's activity is focused on the implementation of modern technology in the field of personalized medicine based on DNA sequencing and diagnostics of genetic diseases. Through a private offer, the company obtained almost PLN 3 million, which it will spend on investments in development and further expansion. Currently, Genomed SA deals with genetic diagnostics in diseases such as: infertility, cancer predisposition, cystic fibrosis, Alzheimer's diseases, hearing loss, metabolic diseases, intellectual disability, cardiomyopathy and obesity. Currently, about 7,000 genetic diseases are known, and with the development of science, this list will be constantly expanded. Personalized medicine is already entering the field of pharmacogenetics, thanks to which the selection of the appropriate dose of the drug and its effectiveness are assessed individually for each person. With the money raised, the company intends to finance the purchase of modern equipment for diagnostic purposes, implement marketing and promotional activities, and prepare for expansion outside the country. - Debut on NewConnect is another step in the development of our business. We have obtained funds that will allow us to implement effective genetic therapies in the future. To achieve this goal, we must have the most modern technology for sequencing and analyzing the entire human genome. It will be used for more effective prophylaxis and medical diagnostics. This service will allow you to read the entire genome and all possible mutations responsible for genetically determined diseases. It is worth emphasizing that so far this technology has been unavailable for most patients due to the enormous costs. Currently, global genetic centers are striving to reduce sequencing time to one day and close to $ 1,000. Thanks to our company, it will soon become a standard also in Poland - says Dr. Marek Zagulski, Genomed has been a leader and expert in the DNA sequencing and synthesis market for 2 years. In 2009, the company's revenues amounted to over PLN 1.7 million with positive EBITDA. In 2010, the company doubled sales revenues to PLN 3.9 million, with a net profit of PLN 0.3 million. In March 2011, Genomed SA carried out a non-public issue of shares, acquiring almost PLN 3 million. The funds obtained in this way will be used by the company for the purchase of diagnostic equipment (devices for reading genomes) and will invest in the development of its activities. The money from investors will help the company to purchase the most modern equipment (partially financed under the Innovative Economy program), to implement genomic technology and services in the field of personalized medicine. This, in turn, will enable Genomed to expand into foreign markets. - An important moment in the company's long-term strategy is the launch of a clinic in which attempts will be made to treat genetic diseases and conduct prophylaxis based on the results of genome sequencing studies - says Dr. Anna Boguszewska-Chachulska, member of the Management Board of Genomed SA The company received co-financing from EU funds in the amount of PLN 2.3 million for the purchase of equipment and business development. Genomed SA was the first in Poland to purchase the GS Junior system for diagnostic purposes. This latest genomic sequencing device was launched just a few months ago by the Roche Group. The machine is characterized by proven technology and high speed of operation, which will contribute to lowering the cost of tests. Genomed SA is an innovative company founded by a group of Polish scientists with several years of experience and significant achievements in the field of molecular biology. For many years they worked as specialists from the state institute, having success in the field of genomics and molecular biology, documented by publications in Nature. The company is the first investment in the field of biotechnology of the MCI.BioVentures fund, thanks to which it has become a leading genetic diagnostics center on the Polish market. It achieved a positive EBITDA result after 20 months from the start of operations and only 15 months from the moment of acquiring an investor. The implementation of the latest technology of sequencing the entire human genomes will enable the obtaining of complete human genetic information. An individual genome record will be the basis for diagnostics, health prophylaxis and an introduction to innovative gene therapy. - This is a breakthrough in the field of genetics that will change the approach to the treatment of genetic diseases. The elimination of the need to repeat sequencing in order to look for further genetic defects means faster waiting time for diagnosis, more effective prophylaxis and a significant reduction in the cost of research work and the final price for the patient - adds Dr. Marek Zagulski. The company's activities to date on the Polish market prove its versatility. In August 2010, the company opened the first private genetic clinic in Warsaw. Thanks to the facility's offer, patients from all over Poland can benefit from the advice and recommendations of a geneticist, both before and after genetic tests. - The creation of the Non-Public Healthcare Institution (NZOZ Genomed) was possible thanks to a highly qualified team. Currently, in order to create a genetic counseling network throughout Poland, we are expanding our team with doctors - clinical geneticists. This will allow the creation of a comprehensive range of diagnostic services for Polish and foreign clients. From the beginning of this year, at the request of the Institute of Mother and Child, as part of the nationwide newborn screening program, we perform sequencing and diagnostic analysis of the gene related to cystic fibrosis - says Agnieszka Sobczyńska-Tomaszewska, MD, head of the NZOZ Genomed. In October this year, Genomed SA, the Polish-Japanese Institute of Information Technology and the Oncology Center - Institute of Maria Skłodowskiej-Curie in Gliwice, will open the first in Poland interdisciplinary doctoral studies "Bioinformatics". The curriculum is distinguished by substantive specialization in the field of personalized medicine, i.e. the study of human genomes for diagnostic purposes. The management board of Genomed decided to participate in this project in order to train the staff of bioinformatics - specialists in the analysis of the human genome, necessary in the near future. The company's authorized advisor is NOBLE Securities SA - Potencjał spółki Genomed S.A. tkwi w wiedzy i adaptacji zaawansowanych technologii. Według twórców firmy istnieją prognozy, zgodnie z którymi w ciągu najbliższych lat dokonają się rewolucyjne zmiany związane z technologią DNA. Wzrost tego rynku na świecie szacuje się na co najmniej 14 proc. rocznie, jednak w Polsce, ze względu na opóźnienie technologiczne związane z późnym przystąpieniem do UE, rynek ten będzie rozwijał się znacznie szybciej – w tempie 30% rocznie. Natomiast sektor spersonalizowanej medycyny oraz terapii genowych dopiero powstaje i jego wzrost jest trudny do oszacowania. Dotychczasowy poziom zaangażowania finansowego krajów rozwiniętych w tę dziedzinę sięga miliardów dolarów. Pozwala to na bardzo optymistyczną ocenę teraźniejszego i przyszłego potencjału rozwoju technologii medycyny spersonalizowanej, także w Polsce - says Norbert Kozioł, Vice President of the Management Board of NOBLE Securities. *** Contact for investors: dr hab. Marek Zagulski President of the Management Board of Genomed SA ul. Ponczowa 12 02-971 Warsaw tel. 22 644 60 19 mobile 516 156 876 e-mail: marek@genomed.pl www.genomed.pl visit us on facebook © Copyright by Genomed SA Created by: Delta Interactive contact GENOMED NZOZ INVESTORS SCIENCE MEDICINE NIFTY privacy policy We use cookies to facilitate the use of our website. If you do not want cookies to be saved on your hard drive, change your browser settings.